Advertisement News Archives - Pharmaceutical Business review
Pharmaceutical Business review is using cookies

ContinueLearn More
Close

News

December 5, 2024

Theratechnologies to license Ionis’ RNA-targeted therapies in Canada

Theratechnologies has entered into a licensing agreement with Ionis Pharmaceuticals to acquire exclusive Canadian rights for two investigational RNA-targeted medicines, olezarsen and donidalorsen.

Theratechnologies to license Ionis’ RNA-targeted therapies in Canada